Clinician applying a soft non-adhesive dressing to a patient's forearm
    Regenerative Therapy

    MUSE Cells and Skin Healing in Epidermolysis Bullosa

    November 5, 202610 min read

    Why People With EB Ask About MUSE Cells for Skin Healing

    Epidermolysis bullosa (EB) makes skin blister and tear from minor friction. Daily life often revolves around dressings, slow wounds and pain. Families asking about MUSE cells for epidermolysis bullosa usually want to know whether wounds could heal faster.

    EB is genetic. Mutations affect proteins that hold the skin layers together at the basement membrane zone. That is why a cell approach is being investigated, and also why it is hard to change.

    What Protects EB Skin Before Any MUSE Cell Option

    • Gentle, non-adhesive dressings and careful handling
    • Infection checks and timely treatment
    • Nutrition support for healing and growth
    • Pain and itch management
    • Regular dermatology review, including skin cancer surveillance in some EB types

    These measures protect skin now. No cell approach removes the need for them.

    Can MUSE Cells Help EB Wounds Heal and What the Study Found

    Fujita and colleagues first reported in a mouse model that intravenous MUSE cells reached damaged skin and could form keratinocytes expressing human basement membrane proteins.

    They then ran an open-label, single-arm study (JapicCTI-184563) in five adults with dystrophic EB. Each person had refractory or recurrent ulcers lasting more than 4 weeks and received one infusion of CL2020, a donor MUSE cell product, containing 1.5 x 107 cells. Follow-up lasted 52 weeks.

    Adverse events were described as mild or self-limiting. One case of arm paraesthesia was considered possibly related and resolved in 14 days. Some early ulcer and pain changes were reported, but ulcer size overall returned to baseline by week 12.

    What MUSE Cell Skin Healing Evidence Still Cannot Prove

    QuestionWhat the pilot showsWhat is still missing
    Is it tolerable?No serious safety signal in five adultsLarger and longer safety data
    Do wounds heal?Early changes that did not last past week 12A controlled trial with lasting endpoints
    Is the skin protein restored?No increase seen in one biopsyTissue evidence in more patients
    Does it apply to children?Children were not includedPaediatric studies

    The study was funded by the product manufacturer, and some authors declared related patents and fees. This is common in early studies but worth knowing.

    MUSE Cell Therapy Approach for Epidermolysis Bullosa

    • How it works: donor MUSE cells are proposed to home to injured skin and support repair. This mechanism comes mainly from animal work.
    • Who may be suitable: only adults matching a formal study protocol. EB type, wound history and overall health matter.
    • What a session involves: the published study used one intravenous infusion with monitoring and a long follow-up schedule.
    • Limits: investigational, early-phase evidence only. It is not gene correction and does not replace wound care.

    Read how MUSE cells differ from MSCs in our MUSE cell therapy overview, the MUSE safety evidence, and how MUSE cells compare with iPS cells. Other regenerative options, such as MSC therapy, need their own EB-specific evidence.

    Questions to Ask Before Trying MUSE Cells for EB

    • Which EB subtype does the study include?
    • Is it registered, and who oversees it?
    • How will wounds be measured, and for how long?
    • What happens to my current wound-care plan?
    • What release testing does the cell product have? See how MUSE cells are isolated and tested.

    Bottom line: the MUSE EB research is an early question, not an established skin-healing treatment.

    Medical References

    Talk to a Doctor Before You Decide

    Bring your genetic diagnosis, wound-care plan and dermatology letters. Our team can explain how the early MUSE epidermolysis bullosa study differs from established skin care.

    Schedule a Consultation

    Frequently Asked Questions

    No. The published human study was a small, open-label pilot in adults. MUSE cell use for epidermolysis bullosa remains investigational.

    Five adults with dystrophic epidermolysis bullosa were enrolled and followed for 52 weeks after a single infusion of the MUSE cell product CL2020.

    No. The authors list the absence of children as a limitation, so the findings cannot be applied to children.

    No. The donor cells are not genetically modified, and the single skin biopsy in the study showed no increase in type VII collagen or anchoring fibrils.

    No. Dressings, infection control, nutrition and pain management stay essential. Any cell study would sit alongside that care, not replace it.

    Related Articles